Congress funds diabetes screening push to catch disease earlier
H.R. 9000 — SCREEN for Type 1 Diabetes Act of 2026 · Filed by Kim Schrier (D-WA) · 41 cosponsors · Introduced May 21, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the CDC to run a national public awareness campaign about Type 1 diabetes screening and early detection, including written materials, public service announcements across media, and grants to states and nonprofits to increase screening access in underserved communities. It authorizes $5 million per year through 2031 and requires a progress report to Congress within one year.
Why we flagged it
The bill's core function is straightforward: establish and fund a CDC-led national campaign to increase awareness and screening for Type 1 diabetes. It is a public health education and prevention measure with no hidden mechanisms or narrow beneficiaries.
What the text implies
- Increased screening rates may lead to earlier diagnosis, which could increase demand for insulin and diabetes management products and services, potentially benefiting pharmaceutical and medical device manufacturers.
- The bill's emphasis on culturally and linguistically competent resources may improve health equity by reaching communities with historically lower screening rates, though implementation success depends on grant recipient quality.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical companies (insulin manufacturers); medical device manufacturers (glucose monitors, pumps); nonprofit health organizations